 
 |
|
Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections
Date: June 30, 2009
Client: Calixa
Summary: SAN DIEGO, June 30, 2009 – Calixa Therapeutics Inc. today announced the initiation of a Phase 2 clinical trial of CXA-101 in patients with complicated urinary tract infections. CXA-101 is a new broad-spectrum, parenteral cephalosporin antibiotic with excellent in vitro and in vivo activity against Pseudomonas aeruginosa, including drug resistant isolates. Calixa is investigating CXA-101 as a potential treatment for serious bacterial infections in hospitalized patients.
|
|
|
|
 |
|
Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211, A Novel Product Candidate for the Treatment of Respiratory Diseases
Date: June 30, 2009
Client: Amira
Summary: San Diego, CA – June 30, 2009 -- Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM211, the company’s oral selective antagonist of the DP2 (also known as CRTH2) receptor. The interim results demonstrate that a sustained pharmacodynamic (PD) effect can be achieved with a single dose of AM211. The pharmacokinetic profile indicates safety multiples as compared to exposures observed in safety species. While there are no DP2 selective antagonists approved for therapeutic use, there is a strong scientific rationale for this target to be a novel treatment of asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis.
|
|
|
|
 |
|
febit First to Offer Newly Published Mouse Genome on a Chip for DNA/RNA Detection and Enrichment
Date: June 29, 2009
Client: febit
Summary: LEXINGTON, Mass. (USA), and HEIDELBERG, Germany - febit technology enables the conversion of new sequence data into biochips for gene expression profiling and sequence capture for Next-Generation Sequencing within days. – febit holding gmbh announced today the launch of the first biochip on the market covering the newly published whole mouse genome. The biochip from febit enables up-to-date profiling and enrichment of genes and SNPs of interest using Gene Expression Profiling, SNP-Detection, ncRNA analysis as well as targeted enrichment of genes for Next-Generation Sequencing (NGS).
|
|
|
|
 |
|
Salvacyl®, developed by Debiopharm, is launched in two European
Date: June 23, 2009
Client: Debiopharm
Summary: Lausanne, Switzerland - Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced that Salvacyl® (also known under the trade names Moapar® and Salvapar®), was launched in Germany in May 2009, by Dr R. Pfleger GmbH. In April 2009, Salvacyl® was also launched on a preliminary basis in Belgium. The effective commercial launch will take place in a couple of months. Salvacyl® contains the active substance triptorelin, a gonadotropin releasing hormone (GnRH) agonist analogue. The product will be prescribed for the reversible reduction of serum testosterone to the level of castration in order to lower sexual drive in adult men suffering from sexual deviations.
|
|
|
|
 |
|
Helix Biopharma Corp Begins Trading on the OTCQX International Market Listing as HXBPF
Date: June 23, 2009
Client: Helix Biopharma
Summary: AURORA, Ontario – Helix BioPharma Corp. (TSX, FSE: “HBP” / OTCQX: “HXBPF”) announced today that it has commenced trading in the U.S. on the OTCQX International Market under the ticker symbol HXBPF. Investors can find real-time quotes, disclosure and financial information about the OTCQX International Market at www.otcqx.com. “Our OTCQX listing provides Helix with enhanced local access to the largest capital market in the world,” said John Docherty, president and chief operating officer of Helix. “Following our recently announced 20-F SEC registration, our OTCQX listing is another important steppingstone towards our ultimate goal of a listing on a major U.S. stock exchange such as The NASDAQ.”
|
|
|
|
|
|
|
Helix Biopharma Announces Q3 2009 Financial Results and Provides Product Development Update
Date: June 15, 2009
Client: Helix Biopharma
Summary: Helix BioPharma Corp. (TSX, FSE: “HBP”) today announced its product development progress, quarterly highlights and financial results for the third quarter of fiscal 2009, ended April 30, 2009. John Docherty, president and chief operating officer, presented at the BioFinance 2009 Investor Conference, where he provided an overview of the Company's leading technology platforms, DOS47TM and BiphasixTM and the Company’s current product development programs, L-DOS47 and Topical Interferon Alpha-2b.
|
|
|
|
 |
|
Molecular Insight Pharmaceuticals, Inc. to Present Clinical, Preclinical Data at the Society of Nuclear Medicine 2009 Annual Meeting
Date: June 11 ,2009
Client: Molecular Insight
Summary: CAMBRIDGE, MA (MARKET WIRE) -- Molecular Insight Pharmaceuticals, Inc. (NasdaqGM:MIPI - News) researchers will present data on the Company's progress in developing novel radiopharmaceuticals that may provide a promising option for molecular imaging of solid tumors, at the Society of Nuclear Medicine (SNM) annual meeting in Toronto. The presentations include clinical data on Molecular Insight's Trofex(TM), a radiolabeled, small-molecule molecular imaging pharmaceutical in development for diagnosis and staging of prostate cancer. Trofex, an internally developed compound, targets prostate specific membrane antigen (PSMA), a protein highly expressed by prostate tumor cells, and has the potential to both detect and, when labeled with a therapeutic isotope, treat metastatic prostate cancer. Data also will be presented on Molecular Insight's recent discovery research oncology projects that have focused on the development of radiolabeled small-molecule inhibitors that target the cancer-related enzymes, carbonic anhydrase IX and seprase.
|
|
|
|
 |
|
Ardea Biosciences Announces Positive Interim Phase 2a Results forLead Gout Drug, RDEA594
Date: June 11, 2009
Client: Ardea
Summary: SAN DIEGO, CA -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced positive interim results from an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, as well as additional positive results from completed Phase 1 studies of RDEA594 in normal, healthy volunteers. The Phase 1 results, along with additional preclinical data, were presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in Copenhagen, Denmark.
|
|
|
|
 |
|
Savara Closes Series A Financing Round
Date: June 9, 2009
Client: Savara
Summary: Savara Pharmaceuticals, a biotechnology inhalation drug delivery company, today announced that it has closed its Series A financing round. The majority of Savara’s existing investors participated in the round, which was made up of biotechnology industry veterans and successful business leaders. Savara will utilize the funds to continue development of its NanoCluster technology in the dry powder therapeutics market and expand into nebulizer and propellant markets.
|
|
|
|
 |
|
Cougar Biotechnology's Board of Directors Recommends Stockholders Accept Johnson & Johnson's $43.00 Per Share Cash Tender Offer
Date: June 5, 2009
Client: Cougar Biotechnology
Summary: Los Angeles, CA - Cougar Biotechnology, Inc. (NASDAQ: CGRB) announced today that its board of directors has unanimously agreed to recommend that stockholders tender their shares to Johnson & Johnson (NASDAQ: JNJ) at the previously announced price of $43.00 per share. The directors also indicated that they intend to tender all their shares of Cougar Biotechnology.
|
|
|
|
 |
|
Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
Date: June 4, 2009
Client: Anadys Pharmaceuticals
Summary: SAN DIEGO - Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced a strategic restructuring to focus its operations on the development of ANA598, in particular a proposed Phase II study in hepatitis C patients of ANA598 in combination with pegylated interferon-alpha and ribavirin.
|
|
|
|
|
|
|
Anadys Pharmaceuticals, Inc. Announces Pricing of Common Stock and Warrant Offering
Date: June 4, 2009
Client: Anadys Pharmaceuticals
Summary: SAN DIEGO - Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced that it has entered into definitive agreements with institutional investors to raise approximately $17.5 million in gross proceeds in a "registered direct" offering through the sale of shares of its common stock and warrants. Anadys estimates that net proceeds from the offering will be approximately $16.2 million, after deducting placement agent fees and estimated offering expenses (not including up to $100,000 of related expenses payable to the placement agent).
|
|
|
|
 |
|
Transfer of Biological Samples from Frozen Storage to Room-Temperature Storage Could Significantly Reduce Electricity Usage, Carbon Footprint and Operating Costs at Major U.S. University, Results from Pilot Project Show
Date: June 3, 2009
Client: Biomatrica
Summary: SAN DIEGO - A major U.S. university could cut its electricity usage by 40 million kilowatt-hours (kWh), reduce its carbon footprint by an estimated 18,000 metric tons and save $16 million in operating costs over the next 10 years by transferring biological samples from frozen storage to room-temperature storage technology, according to the results of a pilot project released by Biomatrica(R) Inc.
|
|
|
|
|
